Department of Immunology, Max Planck Institute for Infection Biology, Charitéplatz 1, D-10117 Berlin, Germany.
Immunity. 2010 Oct 29;33(4):567-77. doi: 10.1016/j.immuni.2010.09.015.
With almost a dozen vaccine candidates in clinical trials, tuberculosis (TB) research and development is finally reaping the first fruits of its labors. Vaccine candidates in clinical trials may prevent TB disease reactivation by efficiently containing the pathogen Mycobacterium tuberculosis (Mtb). Future research should target vaccines that achieve sterile eradication of Mtb or even prevent stable infection. These are ambitious goals that can be reached only by highly cooperative engagement of basic immunologists, vaccinologists, and clinical researchers--or in other words, by translation from basic immunology to vaccine research and development, as well as reverse translation of insights from clinical trials back to hypothesis-driven research in the basic laboratory. Here, we review current and future strategies toward the rational design of novel vaccines against TB, as well as the progress made thus far, and the hurdles that need to be overcome in the near and distant future.
随着十几种疫苗候选物进入临床试验，结核病（TB）的研究和开发终于迎来了辛勤努力的第一批成果。临床试验中的疫苗候选物可能通过有效地控制病原体结核分枝杆菌（Mtb）来预防 TB 疾病的再激活。未来的研究应该针对能够实现 Mtb 无菌根除甚至预防稳定感染的疫苗。这些目标非常宏大，只有通过基础免疫学家、疫苗学家和临床研究人员的高度合作才能实现——换句话说，就是从基础免疫学向疫苗研究和开发进行转化，以及从临床试验的见解反向转化到基础实验室的假设驱动型研究。在这里，我们回顾了目前和未来针对 TB 新型疫苗的合理设计的策略，以及迄今为止所取得的进展，以及在不久的将来和遥远的未来需要克服的障碍。
